Merck (MSD) 
Welcome,         Profile    Billing    Logout  
 296 Products   1145 Diseases   296 Products   3757 Trials   200588 News 


«12345678910111213...22902291»
  • ||||||||||  Steglatro (ertugliflozin) / Pfizer, Merck (MSD)
    Trial primary completion date:  Ertugliflozin in Chronic Heart Failure (clinicaltrials.gov) -  Mar 7, 2025   
    P2,  N=60, Recruiting, 
    Recruiting --> Active, not recruiting Trial primary completion date: Jan 2025 --> Jun 2025
  • ||||||||||  Zolinza (vorinostat) / Merck (MSD)
    Journal:  Enhancing transporter activity in heterologous expression systems with SAHA: a 2500-times more potent and odorless alternative to butyrate. (Pubmed Central) -  Mar 7, 2025   
    Here, we investigated the efficacy of low-cost histone deacetylase (HDAC) inhibitors in enhancing transporter activity, comparing the established sodium butyrate (the sodium salt of butyric acid) with valproate/valproic acid (VPA) and suberoylanilide hydroxamic acid (SAHA, also known as vorinostat)...Our findings advocate for replacing butyrate with SAHA to enhance heterologously expressed transporter activity. This offers a more efficient and user-friendly alternative for functional assays.
  • ||||||||||  Journal:  Navigating Cytomegalovirus Retinitis in a Patient With Myelodysplastic Syndromes Transitioning to Acute Myeloid Leukemia Post Transplant: A Case Study. (Pubmed Central) -  Mar 7, 2025   
    Six months after the transplant, AML relapse was treated with cladribine, cytarabine, granulocyte-colony-stimulating factor/filgrastim, and mitoxantrone (CLAG-M) and venetoclax, leading to measurable clearance of TP53 mutations to undetectable levels by NGS and reduction of CD34+ blasts from 25% to 0%...This case illustrates the aggressive nature of MDS-AML progression, the critical role of vigilant CMV surveillance, and the nuanced approach needed for treatment, balancing efficacy against potential side effects. The successful navigation of these complexities offers valuable insights for similar cases.
  • ||||||||||  Review, Journal:  Inflammatory Bowel Disease in Children: Current Diagnosis and Treatment Strategies. (Pubmed Central) -  Mar 7, 2025   
    Emerging biological therapies, including vedolizumab and ustekinumab, show promise, while novel small molecule therapies such as Janus kinase (JAK) inhibitors are under investigation for potential use in the pediatric population...Future recommendations emphasize the importance of structured transition programs bridging pediatric and adult care, regular updates to clinical guidelines, and the integration of precision medicine to personalize treatment plans. Continued research and collaboration are essential for advancing the understanding and management of PIBD, ensuring that pediatric patients benefit from the most effective, evidence-based care available.
  • ||||||||||  Lynparza (olaparib) / Merck (MSD), AstraZeneca
    Review, Journal, BRCA Biomarker, PARP Biomarker, IO biomarker:  The Landscape of PARP Inhibitors in Solid Cancers. (Pubmed Central) -  Mar 7, 2025   
    Since the approval of the first PARP inhibitor (PARPi), olaparib, several other inhibitors have been developed, expanding the armamentarium available to clinicians in this setting...The clinical trials have demonstrated responses to PARPi which are now also available for the subset of patients with prostate and pancreatic cancer with HR defects. This review summarizes the results obtained in solid tumors with PARPi and their potential use when combined with other agents, including immune checkpoint inhibitors that are likely to further increase the survival of these patients which still needs a dramatic improvement.
  • ||||||||||  Remicade (infliximab) / J&J
    Journal:  Abducens nerve palsy: a rare copresenting sign of incomplete Kawasaki Disease. (Pubmed Central) -  Mar 6, 2025   
    The patient eventually had near-resolution of her abducens nerve palsy with treatment for her underlying Kawasaki disease through aspirin, infliximab, and intravenous immunoglobulin therapy. Abducens nerve palsy is a rare manifestation of Kawasaki disease that may reflect a late diagnosis and an increased risk of coronary artery involvement.
  • ||||||||||  Lyfnua (gefapixant) / Merck (MSD)
    Journal:  The Clinical Approach to Chronic Cough. (Pubmed Central) -  Mar 6, 2025   
    Despite these advances, patient responses remain variable, underscoring the ongoing need for research into the pathophysiology and treatment of RCC. This article reviews current investigations and management options in treating chronic cough and RCC.
  • ||||||||||  zabinostat (CXD101) / IngenOx Therap, Keytruda (pembrolizumab) / Merck (MSD)
    Journal, PD(L)-1 Biomarker, IO biomarker:  Pharmacological activation of STAT1-GSDME pyroptotic circuitry reinforces epigenetic immunotherapy for hepatocellular carcinoma. (Pubmed Central) -  Mar 6, 2025   
    P2
    This article reviews current investigations and management options in treating chronic cough and RCC. Our immunoepigenetic strategy harnesses IFN?-mediated network to augment the cancer-immunity cycle, revealing a self-reinforcing STAT1-GSDME pyroptotic circuitry as the mechanistic basis for an ongoing phase-II trial to tackle ICB resistance (NCT05873244).
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Avastin (bevacizumab) / Roche
    P2 data, Journal:  Phase II Trial of Pembrolizumab in Combination With Bevacizumab for Untreated Melanoma Brain Metastases. (Pubmed Central) -  Mar 6, 2025   
    P2
    Our findings provide insights into the role of SRGs in patients stratification and precision medicine. Pembrolizumab with bevacizumab was well tolerated and demonstrated substantial activity in patients with untreated MBM with promising OS, justifying further evaluation of this regimen.
  • ||||||||||  Review, Journal:  Recent Developments in the Management of Renal Cell Cancer. (Pubmed Central) -  Mar 6, 2025   
    Dual immunotherapy combinations, such as nivolumab plus ipilimumab, and ICI-vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) combinations, including pembrolizumab with axitinib, nivolumab with cabozantinib, and pembrolizumab with lenvatinib, have demonstrated overall survival (OS) benefits in first-line treatment, redefining the standard of care for advanced RCC...Recent results from CONTACT-3 and TiNiVo-2 confirm that ICI rechallenge should be generally discouraged. This review provides a detailed overview of the current evidence supporting immune-based combinations and novel agents such as belzutifan, as well as insights into treatment sequencing strategies for RCC.
  • ||||||||||  linagliptin / Generic mfg., Marizev (omarigliptin) / Merck (MSD)
    Journal:  Glucagon-like peptide-1 receptor agonists but not dipeptidyl peptidase-4 inhibitors reduce alcohol intake. (Pubmed Central) -  Mar 6, 2025   
    This review provides a detailed overview of the current evidence supporting immune-based combinations and novel agents such as belzutifan, as well as insights into treatment sequencing strategies for RCC. Convergent findings across humans, mice, and rats indicate that GLP-1RAs but not DPP-4Is reduce alcohol consumption and may be efficacious in treating AUD.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Journal:  Analysis of immediate 503 thyroid carcinoma deaths: Trend of single institution in 2005-2024. (Pubmed Central) -  Mar 6, 2025   
    Multivariate logistic regression was applied to assess whether the number of patients with anaplastic TC (ATC) at the diagnosis and the number of local-related deaths changed before and after the introduction of Lenvatinib (i.e., 2005-2014 vs. 2015-2024) Results Of the 503 patients, 157 (31%) had ATC, 253 (50%) had papillary TC (PTC), 67 (13%) had follicular TC (FTC), 17 (3%) had poorly differentiated TC, and 9 (2%) had medullary TC...Conclusions ATC, including anaplastic transformation from PTC and FTC, still accounts for approximately 40% of thyroid cancer deaths after the introduction of systematic drug therapy. Respiratory insufficiency is the most common immediate cause of death.
  • ||||||||||  Veozah (fezolinetant) / Astellas
    Journal:  Nonhormonal Treatment of Vasomotor Symptoms of Menopause. (Pubmed Central) -  Mar 6, 2025   
    Neurokinin-3 receptor antagonists, such as fezolinetant, show promising results in reducing hot flashes without affecting cardiovascular health. While more research is needed to further assess long-term outcomes, nonhormonal therapies present a viable and safer alternative for managing VMS, especially for women at risk for cardiovascular complications.
  • ||||||||||  Ilumya (tildrakizumab-asmn) / Sun Pharma, Almirall
    Journal:  Efficacy of tildrakizumab 200 mg for treating difficult-to-treat patient populations with moderate-to-severe plaque psoriasis. (Pubmed Central) -  Mar 6, 2025   
    In this regard, we report a case series describing patients with psoriasis located in different DTT areas or presenting a high Psoriasis Area and Severity Index (PASI) score at baseline and treated ineffectively with prior lines of therapy. Finally, patients achieved complete remission following therapy with tildrakizumab 200 mg (anti-IL-23p19), highlighting its potential efficacy in these patient populations.
  • ||||||||||  Gardasil 9 (human papillomavirus 9-valent vaccine, recombinant) / Merck (MSD)
    Enrollment open:  Testing RG1-VLP Vaccine to Prevent HPV-related Cancers (clinicaltrials.gov) -  Mar 6, 2025   
    P1,  N=33, Recruiting, 
    Active, not recruiting --> Completed Not yet recruiting --> Recruiting
  • ||||||||||  Review, Journal:  Recent Advances in Succinate Dehydrogenase Deficient Gastrointestinal Stromal Tumor Systemic Therapies. (Pubmed Central) -  Mar 6, 2025   
    Additional research into TKI agents with anti-vascular endothelial growth factor receptor (VEGFR) and anti-fibroblast growth factor receptor (FGFR) activity in this clinical setting is needed. Patients with SDH-Def will benefit more broadly from ongoing explorations of treatments with alternative mechanisms of action, especially those that exploit cellular pathways involved in SDH-Def GIST tumorigenesis.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD)
    Review, Journal, Checkpoint inhibition, Mismatch repair, PD(L)-1 Biomarker, IO biomarker:  Mismatch repair deficiency testing for immune checkpoint inhibitor therapy in genitourinary malignancies. (Pubmed Central) -  Mar 6, 2025   
    This review examines laboratory methods (immunohistochemistry, polymerase chain reaction, and next-generation sequencing) for dMMR detection, emphasizing their sensitivity, specificity, and limitations. Using the current literature, we outline considerations for when to test and which method to use when assessing MMR status in genitourinary cancers.
  • ||||||||||  FDA event, Review, Journal:  Clinical Efficacy and Mechanistic Insights of FDA-Approved HDAC Inhibitors in the Treatment of Lymphoma. (Pubmed Central) -  Mar 6, 2025   
    Furthermore, this review seeks to identify gaps in current knowledge and propose directions for future research, including the development of next-generation HDAC inhibitors and strategies for optimizing their clinical use. By consolidating existing evidence, we strive to enhance the understanding of HDACis' role in lymphoma therapy and inspire advancements in their therapeutic potential.
  • ||||||||||  Lytgobi (futibatinib) / Otsuka
    Enrollment closed, Trial completion date, Trial primary completion date:  Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors (clinicaltrials.gov) -  Mar 6, 2025   
    P2,  N=66, Active, not recruiting, 
    No abstract available Recruiting --> Active, not recruiting | Trial completion date: May 2025 --> Jan 2027 | Trial primary completion date: Jan 2025 --> Jul 2025